503 related articles for article (PubMed ID: 28427041)
1. The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease.
Atukeren P; Cengiz M; Yavuzer H; Gelisgen R; Altunoglu E; Oner S; Erdenen F; Yuceakın D; Derici H; Cakatay U; Uzun H
Biomed Pharmacother; 2017 Jun; 90():786-795. PubMed ID: 28427041
[TBL] [Abstract][Full Text] [Related]
2. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
3. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.
Bohnen NI; Kaufer DI; Hendrickson R; Ivanco LS; Lopresti BJ; Koeppe RA; Meltzer CC; Constantine G; Davis JG; Mathis CA; Dekosky ST; Moore RY
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):315-9. PubMed ID: 15716518
[TBL] [Abstract][Full Text] [Related]
4. Ischemia-modified albumin and advanced oxidation protein products as potential biomarkers of protein oxidation in Alzheimer's disease.
Altunoglu E; Guntas G; Erdenen F; Akkaya E; Topac I; Irmak H; Derici H; Yavuzer H; Gelisgen R; Uzun H
Geriatr Gerontol Int; 2015 Jul; 15(7):872-80. PubMed ID: 25345484
[TBL] [Abstract][Full Text] [Related]
5. Profiling donepezil template into multipotent hybrids with antioxidant properties.
Mezeiova E; Spilovska K; Nepovimova E; Gorecki L; Soukup O; Dolezal R; Malinak D; Janockova J; Jun D; Kuca K; Korabecny J
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):583-606. PubMed ID: 29529892
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Lan JS; Zhang T; Liu Y; Yang J; Xie SS; Liu J; Miao ZY; Ding Y
Eur J Med Chem; 2017 Jun; 133():184-196. PubMed ID: 28388521
[TBL] [Abstract][Full Text] [Related]
7. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Davidsson P; Blennow K; Andreasen N; Eriksson B; Minthon L; Hesse C
Neurosci Lett; 2001 Mar; 300(3):157-60. PubMed ID: 11226635
[TBL] [Abstract][Full Text] [Related]
8. Prolonged treatment with donepezil increases acetylcholinesterase expression in the central nervous system.
Zivin M; Pregelj P
Psychiatr Danub; 2008 Jun; 20(2):168-73. PubMed ID: 18587286
[TBL] [Abstract][Full Text] [Related]
9. Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Wang ZM; Cai P; Liu QH; Xu DQ; Yang XL; Wu JJ; Kong LY; Wang XB
Eur J Med Chem; 2016 Nov; 123():282-297. PubMed ID: 27484514
[TBL] [Abstract][Full Text] [Related]
10. Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
Cai P; Fang SQ; Yang HL; Yang XL; Liu QH; Kong LY; Wang XB
Eur J Med Chem; 2018 Sep; 157():161-176. PubMed ID: 30096650
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
12. Management of oxidative stress and other pathologies in Alzheimer's disease.
Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
14. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography.
Ota T; Shinotoh H; Fukushi K; Kikuchi T; Sato K; Tanaka N; Shimada H; Hirano S; Miyoshi M; Arai H; Suhara T; Irie T
Clin Neuropharmacol; 2010; 33(2):74-8. PubMed ID: 19935404
[TBL] [Abstract][Full Text] [Related]
15. Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's drug candidates.
Piemontese L; Tomás D; Hiremathad A; Capriati V; Candeias E; Cardoso SM; Chaves S; Santos MA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1212-1224. PubMed ID: 30160188
[TBL] [Abstract][Full Text] [Related]
16. Does caffeine influence the anticholinesterase and antioxidant properties of donepezil? Evidence from in vitro and in vivo studies.
Oboh G; Ogunsuyi OB; Olonisola OE
Metab Brain Dis; 2017 Apr; 32(2):629-639. PubMed ID: 28091956
[TBL] [Abstract][Full Text] [Related]
17. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.
Darreh-Shori T; Meurling L; Pettersson T; Hugosson K; Hellström-Lindahl E; Andreasen N; Minthon L; Nordberg A
J Neural Transm (Vienna); 2006 Nov; 113(11):1791-801. PubMed ID: 16868793
[TBL] [Abstract][Full Text] [Related]
18. Donepezil hydrochloride: a treatment drug for Alzheimer's disease.
Sugimoto H
Chem Rec; 2001; 1(1):63-73. PubMed ID: 11893059
[TBL] [Abstract][Full Text] [Related]
19. Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease.
Rodrigues Simões MC; Dias Viegas FP; Moreira MS; de Freitas Silva M; Riquiel MM; da Rosa PM; Castelli MR; dos Santos MH; Soares MG; Viegas C
Mini Rev Med Chem; 2014 Jan; 14(1):2-19. PubMed ID: 24251806
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.
Dias Viegas FP; de Freitas Silva M; Divino da Rocha M; Castelli MR; Riquiel MM; Machado RP; Vaz SM; Simões de Lima LM; Mancini KC; Marques de Oliveira PC; Morais ÉP; Gontijo VS; da Silva FMR; D'Alincourt da Fonseca Peçanha D; Castro NG; Neves GA; Giusti-Paiva A; Vilela FC; Orlandi L; Camps I; Veloso MP; Leomil Coelho LF; Ionta M; Ferreira-Silva GÁ; Pereira RM; Dardenne LE; Guedes IA; de Oliveira Carneiro Junior W; Quaglio Bellozi PM; Pinheiro de Oliveira AC; Ferreira FF; Pruccoli L; Tarozzi A; Viegas C
Eur J Med Chem; 2018 Mar; 147():48-65. PubMed ID: 29421570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
